hVIVO plc announced that its consultancy services division,Venn Life Sciences("Venn"), has signed a contract with a major global pharmaceutical client worth €3.2 million over two years. The contract commences in January 2023, with the Venn team in Breda providing dedicated complex clinical pharmacokinetics ("PK") consultancy and programming services to this global pharmaceutical client on a number of drug development programmes across multiple therapeutic areas, to study the absorption, distribution and excretion of drugs within the body.